Hoth Therapeutics, Inc.HOTH
時価総額
$1392.2万
PER
バイオ医薬品の新興企業。HT-005などのカンナビノイド治療薬や前臨床・臨床候補を展開。2017年5月設立、2020年5月にZylö株120,000株取得、2021年12月にHT-005を再許諾。米国中心に展開。
| 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Research and development expense | 785,274 | 2 | 2 | 7 | 5 | 3 | 3 |
| General and administrative expenses | - | - | - | - | - | 4 | 5 |
| Total operating expenses | 2 | 8 | 7 | 14 | 11 | 8 | 8 |
| LOSS FROM OPERATIONS | -2,495,525 | -7,714,997 | -7,301,974 | -14,101,440 | -11,065,554 | -7,692,242 | -8,215,432 |
| Unrealized loss on marketable securities | - | 3,664 | 50,553 | -176,974 | 119,870 | -209,320 | - |
| Change in fair value of investment in joint venture | - | - | - | - | - | - | -581 |
| Dividend and interest income | - | - | - | - | - | - | 27,713 |
| Total other income (expenses), net | - | - | - | -212,265 | 451,140 | - | 27,132 |
| NET LOSS | -2,495,525 | -7,704,636 | -7,197,816 | -14,313,705 | -11,371,953 | -7,845,390 | -8,188,300 |
| Net loss per common share, basic (in Dollars per share) | - | - | - | - | -9.5 | -2.3 | -1.28 |
| Net loss per common share, diluted (in Dollars per share) | - | - | - | - | -9.5 | -2.3 | -1.28 |
| NET LOSS | -2,495,525 | -7,704,636 | -7,197,816 | -14,313,705 | -11,371,953 | -7,845,390 | -8,188,300 |
| Foreign currency translation adjustment | - | - | -15,351 | 32,937 | - | 5,254 | -18,197 |
| Total comprehensive loss | - | - | -7,213,167 | -14,280,768 | -11,367,533 | -7,840,136 | -8,206,497 |